TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00552162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NOTES Transvaginal Cholecystectomy
Description: The gallbladder will be dissected free and will be removed through an incision in the vagina.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NOTES Transvaginal Appendectomy
Description: The appendix will be dissected free and will be removed through an incision in the vagina.
Study: NCT04430985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Day 3 in cycle 3 and 6: 1 mg/kg i.v.
Study: NCT06073691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Practice systematic and regular aerobic physical exercise (walking and running).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise intervention
Description: Practice systematic and regular aerobic physical exercise (walking and running).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03362710

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: simplified tools
Description: 1. Skin temperature on the back of the foot with infra-red thermometry~2. Toe saturometry~3. ABI with an automatic sphygmomanometry~4. Skin Recoloration time at the foot
Study: NCT01011725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK 0773
Description: 25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet b.i.d for 12 weeks
Study: NCT02384460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101-6.0 cream
Description: applied topically once a day for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SD-101-0.0) cream
Description: applied topically once a day for 90 days
Study: NCT06656468

Intervention type: DEVICE
Intervention: Pacemaker and defibrillator
Description: Leadless pacemaker implantation procedure performed accordng to usual clinical practice. The indication for pacemaker implantation will be based on current guidelines.
Study: NCT04535063

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: COVID19 convalescent plasma infusion
Description: intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
Study: NCT03740334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroids are commonly used to treat ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroids are commonly used to treat ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroids are commonly used to treat ALL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
Study: NCT02037126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: This drug will be used as the control. Diphenhydramine is a histamine blocker.
Study: NCT02258412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hand antiseptic with CHG and alcohol
Description: HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol hand sanitizer foam
Description: Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
Study: NCT03417765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 203799
Description: GLP-2 analogue, once weekly, subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 203799
Description: GLP-2 analogue, once weekly, subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 203799
Description: GLP-2 analogue, once weekly, subcutaneous administration
Study: NCT03609164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture-bridge augmentation of single-row repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture-bridge augmentation of single-row repair
Study: NCT02732951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03067220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual outpatient clinic appointment
Description: Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard outpatient clinic appointment
Description: Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
Study: NCT02452359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Versa
Description: The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
Study: NCT03183570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FP-R01-MG-F2
Description: 7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FP-R01-MG-F2
Description: 7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FP-R01-MG-F2
Description: 7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered
Study: NCT03397836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY Intervention
Description: The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
Study: NCT02746731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory and resistance training.
Description: A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
Study: NCT03723239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TricValve® System
Description: The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
Study: NCT01271829

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Avocado supplement
Description: Calories from avocados replace calories of the control lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Avocado included
Description: Calories from avocados will be added to calories from the control lunch
Study: NCT04386148

Intervention type: PROCEDURE
Intervention: Obsidian ASG®
Description: As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
Study: NCT02246894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)
Study: NCT04664296

Intervention type: OTHER
Intervention: Review of medical patient file
Description: Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.

Intervention type: OTHER
Intervention: Phone call interview
Description: less than 15 minutes phone call
Study: NCT01129128

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea product
Description: 5 ml by mouth 3 times per day for 10 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea product
Description: 1 ml by mouth 3 times per day for 10 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: either 5 ml or 1 ml by mouth three times per day for 10 days
Study: NCT02867852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 \[CYP17\]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
Study: NCT02385357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched drink
Description: Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
Study: NCT01600859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for E2609
Description: Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo
Study: NCT02489201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donafenib tosilate tablets
Description: 200mg,bid
Study: NCT01843881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9, 39
Description: Exendin 9,39 is a competitive antagonist of endogenous GLP-1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A saline infusion will be given to match the study drug infusion.
Study: NCT04560218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual Misoprostol
Description: apply drug by Anesthesiologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine Misoprostol
Description: apply drug by surgeon at uterine cornu
Study: NCT04007900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment
Description: PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
Study: NCT02339649

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Puncture
Description: Lumbar Puncture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Puncture
Description: Lumbar Puncture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar Puncture
Description: Lumbar Puncture

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: 60 Minutes MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: 60 Minutes MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: 60 Minutes MRI
Study: NCT01642316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washback
Description: students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test

Intervention type: OTHER
Group type: OTHER
Intervention: routin intervention
Description: students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
Study: NCT04519398

Intervention type: GENETIC
Intervention: Complete thrombophilic profile testing by multiplex PCR
Description: Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~* Factor V Leiden~* Factor V 4070 A\>G (Hr2)~* Factor II G20210A~* Methylenetetrahydrofolate reductase (MTHFR) C677T~* MTHFR A1298C~* Cystathionine β-synthase (CBS) 844ins68~* PAI-1 4G/5G~* Glycoprotein IIIa T1565C (HPA-1a/b)~* ACE-DEL/INS~* Apolipoprotein E (ApoE)~* AGT M235T~* Angiotensin II type 1 receptor (ATR-1) A1166C~* Fibrinogen - 455 G\>A~* Factor XIII Val34Leu

Intervention type: GENETIC
Intervention: Complete thrombophilic profile testing by multiplex PCR
Description: Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~* Factor V Leiden~* Factor V 4070 A\>G (Hr2)~* Factor II G20210A~* Methylenetetrahydrofolate reductase (MTHFR) C677T~* MTHFR A1298C~* Cystathionine β-synthase (CBS) 844ins68~* PAI-1 4G/5G~* Glycoprotein IIIa T1565C (HPA-1a/b)~* ACE-DEL/INS~* Apolipoprotein E (ApoE)~* AGT M235T~* Angiotensin II type 1 receptor (ATR-1) A1166C~* Fibrinogen - 455 G\>A~* Factor XIII Val34Leu

Intervention type: GENETIC
Intervention: Complete thrombophilic profile testing by multiplex PCR
Description: Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~* Factor V Leiden~* Factor V 4070 A\>G (Hr2)~* Factor II G20210A~* Methylenetetrahydrofolate reductase (MTHFR) C677T~* MTHFR A1298C~* Cystathionine β-synthase (CBS) 844ins68~* PAI-1 4G/5G~* Glycoprotein IIIa T1565C (HPA-1a/b)~* ACE-DEL/INS~* Apolipoprotein E (ApoE)~* AGT M235T~* Angiotensin II type 1 receptor (ATR-1) A1166C~* Fibrinogen - 455 G\>A~* Factor XIII Val34Leu
Study: NCT04626336

Intervention type: PROCEDURE
Intervention: Cystectomy
Description: Cystectomy
Study: NCT02931110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL0137
Description: CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
Study: NCT02845388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Study: NCT02074540

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
Study: NCT01150578

Intervention type: DRUG
Intervention: No intervention
Description: No intervention
Study: NCT02845388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Study: NCT02836106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Butter with jam and three slices of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Butter with jam and three slices of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese
Description: Cheese with jam and three slices of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese
Description: Cheese with jam and three slices of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whipped cream
Description: Whipped cream with jam and three slices of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whipped cream
Description: Whipped cream with jam and three slices of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sour cream
Description: Sour cream with jam and three slices of bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sour cream
Description: Sour cream with jam and three slices of bread
Study: NCT00602784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC41

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC41

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC41

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC41

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC41
Study: NCT01573377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol and Cyproterone Acetate
Description: from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
Study: NCT03232944

Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy - MPP
Description: The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
Study: NCT01275027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutralin
Description: 7 capsules taken 15 minutes before each of the three main meals of the day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutralin
Description: 7 capsules taken 15 minutes before each of the three main meals of the day
Study: NCT01427946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT00766103

Intervention type: OTHER
Group type: OTHER
Intervention: mild hypo- and hyperventilation
Description: induction of mild hypo- and hypercarbia
Study: NCT00057070

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Smoking cessation information, collection, and dissemination
Study: NCT01717859

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.
Study: NCT03821532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation Action Plan
Description: Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
Study: NCT01457027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
Study: NCT00377481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: 30 micrograms sc weekly (2 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta [NeoRecormon]
Description: 6000 IU sc weekly (2 doses)